If we use that as an example, Apotex had already gone through the approval process with Health Canada for that particular drug; that was met. When it applied for the first time for its authorization under CAMR, it took less than two weeks for the Commissioner of Patents to issue that authorization, so it was an extremely timely response, very quickly done.
Had the situation arisen that another country wanted that same product and Apotex was able to respond to that need, I would assume that it would simply be reapplying for that particular drug. They had all the information done, they had done all the checks they needed to do with the patentees, they had received all the information they needed, and they had filled out all the forms. It would just have been a resubmission. That didn't happen in this case because no other country notified.
But assuming that all of those requirements were met, it would have been a very timely response, I would imagine.